Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGASUS phase 3 study of pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria
jRCT2031210645Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing Pegcetacoplan with Eculizumab active comparator (2 arms). Started Mar 2022; status: completed.
02
Drugs
pegcetacoplaneculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2031210645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210645.